Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Applying Pharmacogenomics in Drug Discovery and Development
93
55. Yiannakopoulou E. Pharmacogenomics of phase II metabolizing enzymes and
drug transporters: Clinical implications. Pharmacogenomics J 2013;13:105–9.
56. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drugmetabolizing
enzymes: A recent update on clinical implications and endogenous effects.
Pharmacogenomics J 2013;13:1–11.
57. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical
practice. Pharmacol Rev 2006;58:521–90.
58. King HC, Sinha AA. Gene expression profile analysis by DNA microarrays:
Promise and pitfalls. JAMA 2001;286:2280–8.
59. Roncaglioni A, Toropov AA, Toropova AP, Benfenati E. In silico methods to predict
drug toxicity. Curr Opin Pharmacol 2013;13:802–6.
60. Cheng F, Li W, Liu G, Tang Y. In silico ADMET prediction: Recent advances,
current challenges and future trends. Curr Top Med Chem 2013;13:1273–89.
61. Knight A. Non-animal methodologies within biomedical research and toxicity
testing. ALTEX 2008;25:213–31.
62. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S,
Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and
irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000;60:6921–6.
63. Tadokoro J, Kakihata K, Shimazaki M, Shiozawa T, Masatani S, Yamaguchi F,
Sakata Y, Ariyoshi Y, Fukuoka M. Post-marketing surveillance (PMS) of all patients
treated with irinotecan in Japan: Clinical experience and ADR profile of 13,935
patients. Jpn J Clin Oncol 2011;41:1101–11.
64. Ando Y, Hasegawa Y. Clinical pharmacogenetics of irinotecan (CPT-11). Drug
Metab Rev 2005;37:565–74.
65. Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration
of ethnic factors in global drug development, regulatory review, and clinical practice.
Clin Pharmacol Ther 2008;84:287–94.
66. Antman E, Weiss S, Loscalzo J. Systems pharmacology, pharmacogenetics, and
clinical trial design in network medicine. Wiley Interdiscip Rev Syst Biol Med 2012;
4:367–83.
67. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, et al.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med
2010;363:1693–703.
68. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S,
et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung
cancer. Nature 2007;448:561–6.
69. Sheffield LJ, Phillimore HE. Clinical use of pharmacogenomic tests in 2009. Clin
Biochem Rev 2009;30:55–65.
70. Scott SA. Clinical pharmacogenomics: Opportunities and challenges at point of
care. Clin Pharmacol Ther 2013;93:33–5.
71. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450
testing in the clinical setting. Mol Diagn Ther 2013;17:165–84.
72. Gullapalli RR, Desai KV, Santana-Santos L, Kant JA, Becich MJ. Next generation
sequencing in clinical medicine: Challenges and lessons for pathology and biomedical
informatics. J Pathol Inform 2012;3:40.
73. Poste G. Bring on the biomarkers. Nature 2011;469:156–7.
74. McDonald SA. Principles of research tissue banking and specimen evaluation from
the pathologist’s perspective. Biopreserv Biobank 2010;8:197–201.
75. Nestal de Moraes G, Souza PS, Costas FC, Vasconcelos FC, Reis FR, Maia RC.
The interface between BCR-ABL-dependent and -independent resistance signaling
pathways in chronic myeloid leukemia. Leuk Res Treatment 2012;2012:671702.